Pfizer Drug Patent Portfolio
Pfizer owns 31 orange book drugs protected by 114 US patents with Arthrotec having the least patent protection, holding only 1 patent. And Xeljanz Xr with maximum patent protection, holding 15 patents. Given below is the list of Pfizer's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541034 | Nitrile-containing antiviral compounds | 31 Oct, 2041 | Active |
| US12116368 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto | 17 Oct, 2041 | Active |
| US11351149 | Nitrile-containing antiviral compounds | 05 Aug, 2041 | Active |
| US11083724 | Rimegepant for CGRP related disorders | 25 Mar, 2039 | Active |
| US11299500 | Crystalline form of lorlatinib free base hydrate | 04 Oct, 2038 | Active |
| US11065250 | Solid dosage forms of palbociclib | 19 Aug, 2036 | Active |
| US10420749 | Crystalline form of lorlatinib free base | 27 Jul, 2036 | Active |
| US11020376 | Crystalline form of lorlatinib free base | 27 Jul, 2036 | Active |
| US10301262 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders | 21 Jun, 2036 | Active |
| US10676435 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders | 21 Jun, 2036 | Active |
| US11091435 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders | 21 Jun, 2036 | Active |
| US11884626 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders | 21 Jun, 2036 | Active |
| US10414748 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | 13 Apr, 2036 | Active |
| US11168066 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | 13 Apr, 2036 | Active |
| US11891372 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate | 13 Apr, 2036 | Active |
| US11007175 | Methods of treating conditions related to the S1P1 receptor | 06 Jan, 2036 | Active |
| US12156866 | Methods of treating conditions related to the S1P1 receptor | 06 Jan, 2036 | Active |
| US12077533 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | 03 Dec, 2034 | Active |
| US9617258 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | 03 Dec, 2034 | Active |
| US10639309 | Tofacitinib oral sustained release dosage forms | 14 Sep, 2034 | Active |
| US11253523 | Tofacitinib oral sustained release dosage forms | 14 Sep, 2034 | Active |
| US9937181 | Tofacitinib oral sustained release dosage forms | 14 Sep, 2034 | Active |
| US10639309 | Tofacitinib oral sustained release dosage forms | 14 Mar, 2034 | Active |
| US11253523 | Tofacitinib oral sustained release dosage forms | 14 Mar, 2034 | Active |
| US9937181 | Tofacitinib oral sustained release dosage forms | 14 Mar, 2034 | Active |
| US9035074 | Pyrrolo[2,3-D]pyrimidine derivatives | 19 Feb, 2034 | Active |
| US9545405 | Pyrrolo[2,3-D]pyrimidine derivatives | 19 Feb, 2034 | Active |
| US9549929 | Pyrrolo[2,3-D]pyrimidine derivatives | 19 Feb, 2034 | Active |
| US10723730 | Solid forms of a selective CDK4/6 inhibitor | 08 Feb, 2034 | Active |
| US8680111 | Macrocyclic derivatives for the treatment of diseases | 05 Mar, 2033 | Active |
| US8759372 | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt | 25 Feb, 2033 | Active |
| US10189837 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt | 20 Oct, 2031 | Active |
| US8735392 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt | 20 Oct, 2031 | Active |
| US8481546 | CGRP receptor antagonist | 07 Oct, 2031 | Active |
| US8148401 | Benzimidazole derivatives | 30 Jan, 2031 | Active |
| US8314117 | CGRP receptor antagonists | 09 Mar, 2030 | Active |
| US8580841 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | 05 Mar, 2030 | Active |
| US8012976 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | 19 Oct, 2029 | Active |
| US10780088 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | 27 Jul, 2029 | Active |
| US8420650 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | 27 Jul, 2029 | Active |
| US9820985 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | 27 Jul, 2029 | Active |
| US9126932 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders | 22 Jul, 2029 | Active |
| US7772243 | 4-phenylamino-quinazolin-6-yl-amides | 26 Aug, 2028 | Active |
| US8431597 | Benzimidazole derivatives | 29 Jun, 2028 | Active |
| US7815934 | Sequestering subunit and related compositions and methods | 12 Dec, 2027 | Active |
| US7807715 | Pharmaceutical compositions comprising fesoterodine | 07 Dec, 2027 | Active |
| US8088398 | Pharmaceutical compositions comprising fesoterodine | 07 Dec, 2027 | Active |
| US8501723 | Pharmaceutical compositions comprising fesoterodine | 07 Dec, 2027 | Active |
| US7807715 | Pharmaceutical compositions comprising fesoterodine | 07 Jun, 2027 | Active |
| US8088398 | Pharmaceutical compositions comprising fesoterodine | 07 Jun, 2027 | Active |
| US8501723 | Pharmaceutical compositions comprising fesoterodine | 07 Jun, 2027 | Active |
| USRE47739 | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | 05 Mar, 2027 | Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Jun, 2026 | Active |
| US10596162 | Method for treating gefitinib resistant cancer | 02 Feb, 2026 | Active |
| US10603314 | Method for treating gefitinib resistant cancer | 02 Feb, 2026 | Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Dec, 2025 | Active |
| US8790641 | Production of high mannose proteins in plant culture and therapeutic uses thereof | 18 Oct, 2025 | Active |
| US8685443 | Sequestering subunit and related compositions and methods | 03 Jul, 2025 | Active |
| US8623883 | 4-phenylamino-quinazolin-6-yl-amides | 05 May, 2025 | Expired |
| US8227230 | Human lysosomal proteins from plant cell culture | 24 Feb, 2024 | Expired |
| US8741620 | Human lysosomal proteins from plant cell culture | 24 Feb, 2024 | Expired |
| US7220862 | Calcitonin gene related peptide receptor antagonists | 21 Jan, 2024 | Expired |
| US7314883 | Anti-migraine treatments | 05 Dec, 2023 | Expired |
| US6956027 | N-terminally chemically modified protein compositions and methods | 25 Mar, 2023 | Expired |
| US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate | 25 Mar, 2023 | Expired |
| US6936612 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | 16 Jan, 2023 | Expired |
| US7208489 | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones | 16 Jan, 2023 | Expired |
| US7456168 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | 16 Jan, 2023 | Expired |
| US6858650 | Stable salts of novel derivatives of 3,3-diphenylpropylamines | 03 Jan, 2023 | Expired |
| US6858650 | Stable salts of novel derivatives of 3,3-diphenylpropylamines | 03 Jul, 2022 | Expired |
| US6514529 | Oxazolidinone tablet formulation | 15 Sep, 2021 | Expired |
| US6559305 | Linezolid—crystal form II | 29 Jul, 2021 | Expired |
| US6514529 | Oxazolidinone tablet formulation | 15 Mar, 2021 | Expired |
| US6559305 | Linezolid—crystal form II | 29 Jan, 2021 | Expired |
| US6956041 | Pyrrolo[2,3-d]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US7091208 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US7265221 | Pyrrolo[2,3-d]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US7301023 | Chiral salt resolution | 08 Dec, 2020 | Expired |
| US7842699 | Pyrrolo[2,3-D]pyrimidine compounds | 08 Dec, 2020 | Expired |
| US6495157 | Intravaginal clindamycin ovule composition | 20 Jul, 2020 | Expired |
| US6582728 | Spray drying of macromolecules to produce inhaleable dry powders | 24 Jun, 2020 | Expired |
| US6495534 | Stabilized aqueous suspensions for parenteral use | 15 May, 2020 | Expired |
| US6257233 | Dry powder dispersing apparatus and methods for their use | 14 May, 2019 | Expired |
| US6546929 | Dry powder dispersing apparatus and methods for their use | 14 May, 2019 | Expired |
| US7384980 | Derivatives of 3,3-diphenylpropylamines | 11 May, 2019 | Expired |
| US7855230 | Derivatives of 3,3-diphenylpropylamines | 11 May, 2019 | Expired |
| US7985772 | Derivatives of 3,3-diphenylpropylamines | 11 May, 2019 | Expired |
| US8338478 | Derivatives of 3,3-diphenylpropylamines | 11 May, 2019 | Expired |
| USRE44459 | Method for lowering blood glucose | 26 Mar, 2019 | Expired |
| US6187341 | Trovafloxacin mesylate tablet | 20 Jan, 2019 | Expired |
| US6124363 | Dofetilide polymorphs | 09 Oct, 2018 | Expired |
| US6685967 | Methods and compositions for pulmonary delivery of insulin | 11 Sep, 2018 | Expired |
| US6268489 | Azithromycin dihydrate | 31 Jul, 2018 | Expired |
| US6194429 | Alatrofloxacin parenteral compositions | 23 Jul, 2018 | Expired |
| US6103262 | Modified-release metronidazole compositions and methods for making and using same | 15 Aug, 2017 | Expired |
| US6096339 | Dosage form, process of making and using same | 04 Apr, 2017 | Expired |
| US6080756 | Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin | 05 Jul, 2016 | Expired |
| US5763454 | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt | 15 Jun, 2015 | Expired |
| US5688792 | Substituted oxazine and thiazine oxazolidinone antimicrobials | 18 May, 2015 | Expired |
| US5741523 | Stabilized prostaglandin E1 | 21 Apr, 2015 | Expired |
| US5740794 | Apparatus and methods for dispersing dry powder medicaments | 21 Apr, 2015 | Expired |
| US5716338 | Dual-chamber type injection cartridge with bypass connection | 10 Feb, 2015 | Expired |
| US5688792 | Substituted oxazine and thiazine oxazolidinone antimicrobials | 18 Nov, 2014 | Expired |
| US6543448 | Apparatus and methods for dispersing dry powder medicaments | 21 Sep, 2014 | Expired |
| US5997848 | Methods and compositions for pulmonary delivery of insulin | 07 Mar, 2014 | Expired |
| US6051256 | Dispersible macromolecule compositions and methods for their preparation and use | 07 Mar, 2014 | Expired |
| US6423344 | Dispersible macromolecule compositions and methods for their preparation and use | 07 Mar, 2014 | Expired |
| US6592904 | Dispersible macromolecule compositions and methods for their preparation and use | 07 Mar, 2014 | Expired |
| US6737045 | Methods and compositions for the pulmonary delivery insulin | 07 Mar, 2014 | Expired |
| US5601843 | Pharmaceutical tablet composition | 11 Feb, 2014 | Expired |
| US5591454 | Method for lowering blood glucose | 07 Jan, 2014 | Expired |
| US5501673 | Injection cartridge | 16 Apr, 2013 | Expired |
| US5490987 | Tableting of colestipol hydrochloride | 13 Feb, 2013 | Expired |
| US4959366 | Anti-arrhythmic agents | 25 Sep, 2012 | Expired |
Latest Legal Activities on Pfizer's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pfizer.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9545405 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9549929 |
| Second letter to regulating agency to determine regulatory review period | 16 May, 2024 | US8580841 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US8580841 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Apr, 2024 | US8314117 |
|
Information Disclosure Statement (IDS) Filed
Critical
| 04 Apr, 2024 | US11351149 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9545405 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9035074 |
| transaction for FDA Determination of Regulatory Review Period | 13 Mar, 2024 | US8431597 |
| transaction for FDA Determination of Regulatory Review Period | 13 Mar, 2024 | US8148401 |
|
Maintenance Fee Reminder Mailed
Critical
| 11 Mar, 2024 | US8227230 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9035074 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9545405 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US8431597 |
| Post Issue Communication - Certificate of Correction | 28 Feb, 2024 | US11891372 |
Pfizer's Drug Patent Litigations
Pfizer's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6268489. The petitioner , challenged the validity of this patent, with ALLEN et al as the respondent. Click below to track the latest information on how companies are challenging Pfizer's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6858650 | January, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Mylan Pharmaceuticals Inc |
| US6858650 | August, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Torrent Pharmaceuticals Limited |
| US6858650 | August, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Alembic Pharmaceuticals Limited |
| US6858650 | August, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Amerigen Pharmaceuticals Limited |
| US7384980 | January, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Mylan Pharmaceuticals Inc. |
| US7855230 | January, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Mylan Pharmaceuticals Inc. |
| US7985772 | January, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Mylan Pharmaceuticals Inc. |
| US8338478 | January, 2016 |
FWD Entered
(19 Jul, 2017)
| UCB Pharma GmbH | Mylan Pharmaceuticals Inc. |
| US6685967 | April, 2002 |
Decision
(23 Jan, 2003)
| PATTON et al | |
| US6268489 | January, 1 |
Decision
(15 Apr, 1998)
| ALLEN et al | |
Pfizer Drug Patents' Oppositions Filed in EPO
Pfizer drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 09, 2011, by Wibbelmann, Jobst. This opposition was filed on patent number EP02781589A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP18186675A | Jan, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP18186675A | Jan, 2022 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP18186675A | Jan, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP18186675A | Jan, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP14726410A | Dec, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP14726410A | Dec, 2021 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP14726410A | Dec, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP14726410A | Dec, 2021 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP14726410A | Dec, 2021 | Greiner, Elisabeth | Granted and Under Opposition |
| EP14726410A | Nov, 2021 | Aera A/S | Granted and Under Opposition |
| EP16726192A | Aug, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP16726192A | Aug, 2020 | Synthon BV | Granted and Under Opposition |
| EP16726192A | Aug, 2020 | Hexal AG | Granted and Under Opposition |
| EP16726192A | Aug, 2020 | Galenicum Health S.L. | Granted and Under Opposition |
| EP16726192A | Aug, 2020 | Hoffmann Eitle | Granted and Under Opposition |
| EP16726192A | Aug, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP14705884A | Jun, 2019 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP14705884A | Jun, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP14705884A | Jun, 2019 | Generics (UK) Ltd | Granted and Under Opposition |
| EP06720163A | Nov, 2011 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | Granted and Under Opposition |
| EP02781589A | Nov, 2011 | Wibbelmann, Jobst | Opposition rejected |
Pfizer's Family Patents
Pfizer Drug List
Given below is the complete list of Pfizer's drugs and the patents protecting them.
1. Arthrotec
Arthrotec is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5601843 | Pharmaceutical tablet composition |
11 Feb, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arthrotec's drug page
2. Caverject
Caverject is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5741523 | Stabilized prostaglandin E1 |
21 Apr, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caverject's drug page
3. Caverject Impulse
Caverject Impulse is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5716338 | Dual-chamber type injection cartridge with bypass connection |
10 Feb, 2015
(10 years ago)
| Expired |
| US5501673 | Injection cartridge |
16 Apr, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caverject Impulse's drug page
4. Cibinqo
Cibinqo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9035074 | Pyrrolo[2,3-D]pyrimidine derivatives |
19 Feb, 2034
(8 years from now)
| Active |
| US9545405 | Pyrrolo[2,3-D]pyrimidine derivatives |
19 Feb, 2034
(8 years from now)
| Active |
| US9549929 | Pyrrolo[2,3-D]pyrimidine derivatives |
19 Feb, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cibinqo's drug page
5. Cleocin
Cleocin is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6495157 | Intravaginal clindamycin ovule composition |
20 Jul, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cleocin's drug page
Explore Our Curated Drug Screens
6. Colestid
Colestid is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5490987 | Tableting of colestipol hydrochloride |
13 Feb, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Colestid's drug page
7. Covera-hs
Covera-hs is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6096339 | Dosage form, process of making and using same |
04 Apr, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Covera-hs's drug page
8. Daurismo
Daurismo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10414748 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
13 Apr, 2036
(10 years from now)
| Active |
| US11168066 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
13 Apr, 2036
(10 years from now)
| Active |
| US11891372 | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
13 Apr, 2036
(10 years from now)
| Active |
| US8148401 | Benzimidazole derivatives |
30 Jan, 2031
(5 years from now)
| Active |
| US8431597 | Benzimidazole derivatives |
29 Jun, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daurismo's drug page
9. Depo-subq Provera 104
Depo-subq Provera 104 is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6495534 | Stabilized aqueous suspensions for parenteral use |
15 May, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depo-subq Provera 104's drug page
10. Elelyso
Elelyso is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8790641 | Production of high mannose proteins in plant culture and therapeutic uses thereof |
18 Oct, 2025
(5 months from now)
| Active |
| US8227230 | Human lysosomal proteins from plant cell culture |
24 Feb, 2024
(1 year, 2 months ago)
| Expired |
| US8741620 | Human lysosomal proteins from plant cell culture |
24 Feb, 2024
(1 year, 2 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elelyso's drug page
11. Exubera
Exubera is protected by 11 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6582728 | Spray drying of macromolecules to produce inhaleable dry powders |
24 Jun, 2020
(4 years ago)
| Expired |
| US6257233 | Dry powder dispersing apparatus and methods for their use |
14 May, 2019
(5 years ago)
| Expired |
| US6546929 | Dry powder dispersing apparatus and methods for their use |
14 May, 2019
(5 years ago)
| Expired |
| US6685967 | Methods and compositions for pulmonary delivery of insulin |
11 Sep, 2018
(6 years ago)
| Expired |
| US5740794 | Apparatus and methods for dispersing dry powder medicaments |
21 Apr, 2015
(10 years ago)
| Expired |
| US6543448 | Apparatus and methods for dispersing dry powder medicaments |
21 Sep, 2014
(10 years ago)
| Expired |
| US5997848 | Methods and compositions for pulmonary delivery of insulin |
07 Mar, 2014
(11 years ago)
| Expired |
| US6051256 | Dispersible macromolecule compositions and methods for their preparation and use |
07 Mar, 2014
(11 years ago)
| Expired |
| US6423344 | Dispersible macromolecule compositions and methods for their preparation and use |
07 Mar, 2014
(11 years ago)
| Expired |
| US6592904 | Dispersible macromolecule compositions and methods for their preparation and use |
07 Mar, 2014
(11 years ago)
| Expired |
| US6737045 | Methods and compositions for the pulmonary delivery insulin |
07 Mar, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exubera's drug page
12. Flagyl Er
Flagyl Er is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6103262 | Modified-release metronidazole compositions and methods for making and using same |
15 Aug, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Flagyl Er's drug page
13. Glucotrol Xl
Glucotrol Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE44459 | Method for lowering blood glucose |
26 Mar, 2019
(6 years ago)
| Expired |
| US5591454 | Method for lowering blood glucose |
07 Jan, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucotrol Xl's drug page
14. Ibrance
Ibrance is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11065250 | Solid dosage forms of palbociclib |
19 Aug, 2036
(11 years from now)
| Active |
| US10723730 | Solid forms of a selective CDK4/6 inhibitor |
08 Feb, 2034
(8 years from now)
| Active |
| USRE47739 | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
05 Mar, 2027
(1 year, 9 months from now)
| Active |
| US6936612 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
16 Jan, 2023
(2 years ago)
| Expired |
| US7208489 | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
16 Jan, 2023
(2 years ago)
| Expired |
| US7456168 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
16 Jan, 2023
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ibrance's drug page
15. Litfulo
Litfulo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12116368 | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
17 Oct, 2041
(16 years from now)
| Active |
| US12077533 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
03 Dec, 2034
(9 years from now)
| Active |
| US9617258 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
03 Dec, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Litfulo's drug page
16. Lorbrena
Lorbrena is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11299500 | Crystalline form of lorlatinib free base hydrate |
04 Oct, 2038
(13 years from now)
| Active |
| US10420749 | Crystalline form of lorlatinib free base |
27 Jul, 2036
(11 years from now)
| Active |
| US11020376 | Crystalline form of lorlatinib free base |
27 Jul, 2036
(11 years from now)
| Active |
| US8680111 | Macrocyclic derivatives for the treatment of diseases |
05 Mar, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lorbrena's drug page
17. Nurtec Odt
Nurtec Odt is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11083724 | Rimegepant for CGRP related disorders |
25 Mar, 2039
(13 years from now)
| Active |
| US8759372 | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
25 Feb, 2033
(7 years from now)
| Active |
| US8314117 | CGRP receptor antagonists |
09 Mar, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nurtec Odt's drug page
18. Paxlovid (copackaged)
Paxlovid (copackaged) is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541034 | Nitrile-containing antiviral compounds |
31 Oct, 2041
(16 years from now)
| Active |
| US11351149 | Nitrile-containing antiviral compounds |
05 Aug, 2041
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Paxlovid (copackaged)'s drug page
19. Talzenna
Talzenna is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10189837 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
20 Oct, 2031
(6 years from now)
| Active |
| US8735392 | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
20 Oct, 2031
(6 years from now)
| Active |
| US8012976 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
19 Oct, 2029
(4 years from now)
| Active |
| US10780088 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
27 Jul, 2029
(4 years from now)
| Active |
| US8420650 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
27 Jul, 2029
(4 years from now)
| Active |
| US9820985 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
27 Jul, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Talzenna's drug page
20. Tikosyn
Tikosyn is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6124363 | Dofetilide polymorphs |
09 Oct, 2018
(6 years ago)
| Expired |
| US4959366 | Anti-arrhythmic agents |
25 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tikosyn's drug page
21. Toviaz
Toviaz is protected by 12 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7807715
(Pediatric)
| Pharmaceutical compositions comprising fesoterodine |
07 Dec, 2027
(2 years from now)
| Active |
| US8088398
(Pediatric)
| Pharmaceutical compositions comprising fesoterodine |
07 Dec, 2027
(2 years from now)
| Active |
| US8501723
(Pediatric)
| Pharmaceutical compositions comprising fesoterodine |
07 Dec, 2027
(2 years from now)
| Active |
| US7807715 | Pharmaceutical compositions comprising fesoterodine |
07 Jun, 2027
(2 years from now)
| Active |
| US8088398 | Pharmaceutical compositions comprising fesoterodine |
07 Jun, 2027
(2 years from now)
| Active |
| US8501723 | Pharmaceutical compositions comprising fesoterodine |
07 Jun, 2027
(2 years from now)
| Active |
| US6858650
(Pediatric)
| Stable salts of novel derivatives of 3,3-diphenylpropylamines |
03 Jan, 2023
(2 years ago)
| Expired |
| US6858650 | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
03 Jul, 2022
(2 years ago)
| Expired |
| US7384980 | Derivatives of 3,3-diphenylpropylamines |
11 May, 2019
(6 years ago)
| Expired |
| US7855230 | Derivatives of 3,3-diphenylpropylamines |
11 May, 2019
(6 years ago)
| Expired |
| US7985772 | Derivatives of 3,3-diphenylpropylamines |
11 May, 2019
(6 years ago)
| Expired |
| US8338478 | Derivatives of 3,3-diphenylpropylamines |
11 May, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Toviaz's drug page
22. Trovan
Trovan is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6187341 | Trovafloxacin mesylate tablet |
20 Jan, 2019
(6 years ago)
| Expired |
| US5763454 | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt |
15 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trovan's drug page
23. Trovan Preservative Free
Trovan Preservative Free is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6194429 | Alatrofloxacin parenteral compositions |
23 Jul, 2018
(6 years ago)
| Expired |
| US6080756 | Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin |
05 Jul, 2016
(8 years ago)
| Expired |
| US5763454 | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt |
15 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trovan Preservative Free's drug page
24. Troxyca Er
Troxyca Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7815934 | Sequestering subunit and related compositions and methods |
12 Dec, 2027
(2 years from now)
| Active |
| US8685443 | Sequestering subunit and related compositions and methods |
03 Jul, 2025
(a month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Troxyca Er's drug page
25. Velsipity
Velsipity is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10301262 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
21 Jun, 2036
(11 years from now)
| Active |
| US10676435 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders |
21 Jun, 2036
(11 years from now)
| Active |
| US11091435 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders |
21 Jun, 2036
(11 years from now)
| Active |
| US11884626 | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders |
21 Jun, 2036
(11 years from now)
| Active |
| US11007175 | Methods of treating conditions related to the S1P1 receptor |
06 Jan, 2036
(10 years from now)
| Active |
| US12156866 | Methods of treating conditions related to the S1P1 receptor |
06 Jan, 2036
(10 years from now)
| Active |
| US8580841 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
05 Mar, 2030
(4 years from now)
| Active |
| US9126932 | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
22 Jul, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Velsipity's drug page
26. Vizimpro
Vizimpro is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7772243 | 4-phenylamino-quinazolin-6-yl-amides |
26 Aug, 2028
(3 years from now)
| Active |
| US10596162 | Method for treating gefitinib resistant cancer |
02 Feb, 2026
(8 months from now)
| Active |
| US10603314 | Method for treating gefitinib resistant cancer |
02 Feb, 2026
(8 months from now)
| Active |
| US8623883 | 4-phenylamino-quinazolin-6-yl-amides |
05 May, 2025
(4 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vizimpro's drug page
27. Xeljanz
Xeljanz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE41783
(Pediatric)
| Pyrrolo[2,3-D]pyrimidine compounds |
08 Jun, 2026
(1 year, 29 days from now)
| Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2025
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeljanz's drug page
28. Xeljanz Xr
Xeljanz Xr is protected by 15 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10639309
(Pediatric)
| Tofacitinib oral sustained release dosage forms |
14 Sep, 2034
(9 years from now)
| Active |
| US11253523
(Pediatric)
| Tofacitinib oral sustained release dosage forms |
14 Sep, 2034
(9 years from now)
| Active |
| US9937181
(Pediatric)
| Tofacitinib oral sustained release dosage forms |
14 Sep, 2034
(9 years from now)
| Active |
| US10639309 | Tofacitinib oral sustained release dosage forms |
14 Mar, 2034
(8 years from now)
| Active |
| US11253523 | Tofacitinib oral sustained release dosage forms |
14 Mar, 2034
(8 years from now)
| Active |
| US9937181 | Tofacitinib oral sustained release dosage forms |
14 Mar, 2034
(8 years from now)
| Active |
| USRE41783
(Pediatric)
| Pyrrolo[2,3-D]pyrimidine compounds |
08 Jun, 2026
(1 year, 29 days from now)
| Active |
| USRE41783 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2025
(6 months from now)
| Active |
| US6956027 | N-terminally chemically modified protein compositions and methods |
25 Mar, 2023
(2 years ago)
| Expired |
| US6965027 | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
25 Mar, 2023
(2 years ago)
| Expired |
| US6956041 | Pyrrolo[2,3-d]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
| US7091208 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
| US7265221 | Pyrrolo[2,3-d]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
| US7301023 | Chiral salt resolution |
08 Dec, 2020
(4 years ago)
| Expired |
| US7842699 | Pyrrolo[2,3-D]pyrimidine compounds |
08 Dec, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeljanz Xr's drug page
29. Zavzpret
Zavzpret is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8481546 | CGRP receptor antagonist |
07 Oct, 2031
(6 years from now)
| Active |
| US7220862 | Calcitonin gene related peptide receptor antagonists |
21 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US7314883 | Anti-migraine treatments |
05 Dec, 2023
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zavzpret's drug page
30. Zithromax
Zithromax is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6268489 | Azithromycin dihydrate |
31 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zithromax's drug page
31. Zyvox
Zyvox is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6514529
(Pediatric)
| Oxazolidinone tablet formulation |
15 Sep, 2021
(3 years ago)
| Expired |
| US6559305
(Pediatric)
| Linezolid—crystal form II |
29 Jul, 2021
(3 years ago)
| Expired |
| US6514529 | Oxazolidinone tablet formulation |
15 Mar, 2021
(4 years ago)
| Expired |
| US6559305 | Linezolid—crystal form II |
29 Jan, 2021
(4 years ago)
| Expired |
| US5688792
(Pediatric)
| Substituted oxazine and thiazine oxazolidinone antimicrobials |
18 May, 2015
(9 years ago)
| Expired |
| US5688792 | Substituted oxazine and thiazine oxazolidinone antimicrobials |
18 Nov, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyvox's drug page